4.8 (494) · € 31.00 · En Stock
Frontiers The PD-1/PD-L1 Pathway Affects the Expansion and
Blockade of PD-1/PD-L1 increases effector T cells and aggravates
EGR1 Monoclonal Antibody (HEGR1DS), PE (12-9851-42)
Pamela S. Ohashi's research works University of Toronto, Toronto
IJMS, Free Full-Text
APExBIO - Vacuolin-1 , lysosomal exocytosis inhibitor , CAS
Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Identification of Potential Plk1 Targets in a Cell-Cycle Specific
Frontiers The PD-1/PD-L1 Pathway Affects the Expansion and
PD-1 blockade therapy promotes infiltration of tumor-attacking
PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T